Among the numerous genetic alterations which have been connected to resistance to cetuximab, activating mutations in the KRAS gene are especially important in colorectal cancer regimens (Karapetis et al. 2008; Lievre et al. 2006). The gene discussed is KRAS; the disease is colorectal cancer.